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Abstract
Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year
in Europe. However, there is a paucity of data on the current management in real life, including factors influencing
treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the
corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care
and needs as well as potential gaps for improvement.
Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in
seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the
characteristics and the management of patients with VTE, the use of health care resources, and to provide data to
estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or
specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical
outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the
care environment in which patients with VTE are managed in each of the participating countries. Patients were
eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed
first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or
both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3,
6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls.
Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year.
Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE
and their acute and mid-term management, as well as into drug utilization and the use of health care resources in
acute first-time and/or recurrent VTE across Europe in clinical practice.
Trial registration: Registered in DRKS register, ID number: DRKS00004795
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Background
Acute venous thromboembolism (VTE), including deep-
vein thrombosis (DVT) and pulmonary embolism (PE) is
a common disorder with an annual incidence of approxi-
mately 1 or 2 cases per 1000 persons in the general
population [1–3]. Patients with DVT and PE have in-
creased morbidity and mortality both related to these
conditions and also associated co-morbidities such as
cancer, medical conditions and surgical procedures [4].
The main objective of anticoagulant therapy for patients
with acute VTE is to prevent thrombus extension,
embolization and recurrences. According to current
practice guidelines the management of patients with acute
VTE consists of an initial treatment with bodyweight-
adjusted subcutaneous low molecular weight heparin
(LMWH); adjusted-dose intravenous or fixed dose sub-
cutaneous unfractionated heparin (UFH); or bodyweight-
adjusted subcutaneous fondaparinux followed by long-
term treatment with a vitamin K antagonist (VKA) or
non-VKA oral anticoagulants (NOACs) [5]. For the treat-
ment of PE the current 2014 European Society of Cardi-
ology Guidelines on the diagnosis and management of
acute PE recommend the use of NOACs as alternatives to
VKAs [6].
Patients should receive parenteral anticoagulants (ei-
ther LMWH or UFH or fondaparinux) for at least five
days. It is recommended to start VKA on the first treat-
ment day because of the slow onset of action. LMWH,
UFH, or fondaparinux therapy may be discontinued
when the VKA has reached its therapeutic level as indi-
cated by an international normalized ratio (INR) ≥2 at
two or more measurements at least 24 h apart. VKA
therapy should be continued for at least 3 months. For
most patients with a DVT and/or PE secondary to a
transient risk factor the currently recommended dur-
ation of treatment is sufficient, although extension by
another 3 to 6 months of therapy may be indicated in
some patients [3]. However, for those with unpro-
voked DVT or PE, the recommendation is to evaluate
the risks and benefits for prolonged therapy. In either
case, the VKA dosage regimen needs to be adjusted
to maintain the INR in the therapeutic range (target
2.5, range 2.0 to 3.0).
VKAs (such as the coumarins: warfarin, acenocou-
marol or phenprocoumon) are indirect coagulation in-
hibitors, which act by blocking the vitamin K-dependent
liver synthesis of the plasma coagulation factors II, VII,
IX and X. They were the only oral anticoagulants avail-
able for over 50 years. Randomized controlled trials have
shown that warfarin, the most commonly used VKA,
targeted to an INR between 2.0 and 3.0, reduces the risk
of recurrent venous thromboembolic complications in
subjects with DVT or PE by 80% to 90% [5,7–9]. How-
ever, the use of VKAs is complicated by several inherent
problems including a delayed onset of antithrombotic
action; a narrow therapeutic window that requires close
laboratory monitoring using the INR; an unpredictable
and variable pharmacological response; and food and
drug interactions requiring frequent monitoring and
dosage adjustment [10].
Recently developed oral anticoagulants that are di-
rected against factor Xa or thrombin (factor IIa) over-
come some limitations of standard therapy including the
need for injections of parenteral anticoagulants and for
regular dose adjustments on the basis of laboratory
monitoring [11–13]. However, VKAs are still often pre-
scribed and although NOACs are widely approved in
Europe, use of NOACs is limited by national guidelines
and reimbursement. In Europe, little is known about
which factors influence the individual VTE patients’
utilization of health care resources and the correspond-
ing costs derived in hospitals, out of hospitals or in spe-
cialized centres during the period between confirmed
first-time or recurrent VTE treatment and 12 months of
follow-up.
Study aims
The key aims of the PREFER in VTE registry were to
assess the real-life acute and mid-term management of
patients with VTE, the use of health care resources, and
to provide data to estimate the costs for 12-months
treatment following a first-time and/or recurrent VTE
diagnosis in hospitals or specialized centers in Europe.
In addition, existing anticoagulant treatment patterns,
patient pathways, clinical outcomes, treatment satisfac-
tion, and health related quality of life (HR-QoL) were
documented.
Primary objectives
The primary objective of this registry was to assess the
12-months direct healthcare resource use and to provide
data to estimate the costs following an acute first time
or recurrent VTE. In addition, detailed insights into the
patients’ characteristics, the management of acute VTE
(in particular DVT and/or PE) with specific focus on
prevention of VTE recurrences and its treatment-related
events such as bleeding, recurrence of DVT/PE, myocar-
dial infarction, stroke, systemic embolic events, post
thrombotic syndrome, cardiovascular (CV) events, and
death were collected. DVT was defined as DVT alone
and PE as PE with or without DVT.
Secondary objectives
The secondary objectives of this study were to 1) de-
scribe the treatment satisfaction, HR-QoL, and clinical
outcomes following first time or recurrent VTE; 2) to
explore the potential relationships between different an-
ticoagulants and duration of therapy, resource use,
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estimated costs, treatment satisfaction, HR-QoL, and
clinical outcomes; 3) to explore possible geographic vari-
ations in the management of VTE patients, duration of
therapy, resource use, estimated costs and treatment
satisfaction.
Methods and design
The PREFER in VTE registry was a prospective, observa-
tional, multicenter study with a follow-up of 12 months
and enrolled 3,545 consecutive patients who gave
informed consent from 381 centers (311 active centers
enrolling ≥1 patient) in seven European countries
including Austria, France, Germany, Italy, Spain,
Switzerland, and the UK between January 2013 and July
2014. Data were recorded at baseline of the acute VTE
and prospectively documented during follow-up at 1, 3,
6 and 12 months (Fig. 1).
Patient information was collected from two different
sources: collection of baseline data took place in the
hospitals or specialized centers at the time of the diag-
nosis of the acute VTE. Hospitals or specialized/primary
care centers could also opt to follow-up the patients at 1
month. As hospital based investigators do not always see
the patient during the following 12 months as part of
the routine clinical care, patients were followed by tele-
phone calls. Patients agreed to provide contact details
for the planned follow-up calls with the permission to
hand the contact details over to the respective local con-
tact research organization (CRO).
This registry was conducted in accordance with the
Declaration of Helsinki and adheres to the principles of
Good Epidemiology Practice, and applicable regulatory
requirements. The responsible ethics committees of the
participating countries and the hospital-based institu-
tional review boards approved the protocol of this regis-
try. Patients enrolled into this registry provided written
informed consent. Due to the nature of a non-
interventional registry, no specific treatments, tests, or
procedures were mandated or withheld from the
patients. Treatment pattern and treatment initiation,
continuation or changes were solely at the discretion of
the physician and the patient. There was no attempt to
influence the prescribing patterns of any individual
treating physician. All medication was prescribed in the
usual standard of care and was not provided by the
study sponsor. Participation in the study in no way influ-
enced payment or reimbursement for any treatment
received by patients during the study. Patients were free
to withdraw from the registry at any time.
Selection of sites
Investigator sites were representative for the specific
local distribution of primary and secondary care settings
in each participating country. A sufficient number of
sites were identified including hospitals and specialized
centers to best represent current practice of VTE diag-
nosis and treatment in each particular country. Most
centers contacted for participation were randomly se-
lected, others were chosen from experienced centers
and all centers were asked to provide institutional de-
tails in a short site feasibility questionnaire before be-
ing selected. Each active site consecutively recruited
at least 1 and up to 60 patients. The enrollment
period was 12 months.
Selection of patients
Patients from Austria, France, Germany, Italy, Spain,
Switzerland and the UK who gave written informed con-
sent were consecutively enrolled into the registry in hos-
pitals or specialized centers if they were at least 18 years
old, had a confirmed first time or recurrent symptomatic
VTE defined as either distal or proximal DVT, PE [3] or
both, provided telephone contact details for follow-up
calls, and were not simultaneously participating in a
double blind interventional study.
We expect the parameters measured will vary between
patients on the conventional pathway of treatment and
those using NOACs and therefore the comparison be-
tween those following the conventional pathway and
those on the NOACs and the impact of NOACs on
QoL, Resource consumption and mostly health care
utilization will be examined.
The study aimed to a achieve a general ratio of
PE:DVT which was approximately 2:3 resulting in a
total number of PE (with or without DVT) patients
Fig. 1 Time course of the data collection from baseline to 12 months follow-up
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of n = 1,399 and a total number of patients with DVT
(distal or proximal) of n = 2,056 (Fig. 2).
Documented variables
The enrolling study site documented all patient related
baseline data at the time of the acute VTE. The follow-
up calls were performed centrally by local CROs. The
CROs used standardized questionnaires to get all re-
quired information (i.e. recurrence of VTE, bleeding,
post-thrombotic syndrome, death, hospitalization, as
well as medications and treatments, QoL and patient
satisfaction (Perception of Anticoagulant Treatment
Questionnaire 2 [PACT-Q2], Venous Insufficiency Epi-
demiological and Economic Study [Veines-QoL/Sym] or
Pulmonary Embolism Quality of Life [PEmb-QoL]), re-
source consumption / health care utilization). Patient
diaries were distributed to facilitate the standardized
structured phone calls. The treatment satisfaction ques-
tionnaire (PACT-Q2), the disease specific questionnaire
(PEmb-QoL or Veines-QoL/Sym) and the QoL question-
naire (EQ 5D–5L) were filled out at baseline, and re-
peated by post at 1, 3, 6 and 12 months after first
diagnosis of acute VTE.
Table 1 displays the variables documented at baseline
and at the follow-up visits at 1, 3, 6 and 12 months. The
data sources used in this study were clinical records,
self-reports, claims, and data from telephone interviews.
Patients’ treatment satisfaction and quality of life
Data on patients’ treatment satisfaction and QoL were
documented using specific patient-questionnaires. The
following questionnaires were part of the evaluation:
Quality of Life Questionnaire (EQ 5D–5L)
EQ 5D-5L is a standardized measure of health status
developed by the EuroQol Group in order to provide
a simple, generic measure of health for clinical and
economic assessment [14]. Applicable to a wide range
of health conditions and treatments, it provides a
simple descriptive profile and a single index value for
health status that can be used in the clinical and eco-
nomic evaluation of health care as well as in popula-
tion health surveys.
Treatment Satisfaction Questionnaire
Anticoagulation-specific questionnaire PACT-Q. The
‘Perception of AntiCoagulant Treatment Questionnaire’
was developed to assess patients’ expectations of, and
satisfaction with their anticoagulant treatment [15–17].
Veines-QoL/Sym
The Veines-QoL/Sym is a patient-based questionnaire
designed for self-completion and measures the impact of
DVT on symptoms and QoL from the patient’s perspec-
tive; this was only completed by patients with DVT [18].
PEmb-QoL
The PEmb-QoL questionnaire was modeled on the QoL
after DVT (Veines-QoL/Sym) questionnaire. This ques-
tionnaire, like the Veines-QoL/Sym, assesses the fre-
quency of symptoms, the time of day which the
complaints are their worst, and activities of daily living,
as well as work-related problems. However, the PEmb-
QoL questionnaire is distinct from the Veines-QoL/Sym
in the inclusion of pulmonary-specific symptoms, adding
questions on limitations in daily physical activities, and
Fig. 2 Patient enrollment
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extending the number of questions on emotional func-
tioning [19].
The PEmb-QoL was only filled out by patients with
PE.
Data management and quality control
Data entry was performed by the physician or study
nurse via a secure website directly into an electronic
database. This approach allowed online checks for
plausibility and integrity.
There were three strategies for data quality checks:
validations that occurred at the time of data entry
(i.e., “front-end”), a second, more sophisticated quality
control program that ran as a prelude to the creation
of the analysis data set and on-site data monitoring
by the CRO.
Front-end data checks are advantageous because mis-
takes are caught and corrected at the time of entry. Cer-
tain data elements can be required, while other elements
may allow missing values. Additionally, parameters were
defined to allow entry of only those records that met the
inclusion criteria.
Thirdly, prior to the creation of the analytic dataset,
more extensive quality control processes were per-
formed. These checks, programmed in SAS (release 9.2
or higher; Cary, NC, USA), included parent–child edits,
consistency edits, and data transformations that facili-
tated analyses.
Sample size
In order to provide meaningful data on reimbursement
from different agencies in each participating country,
and because significant variation was expected between
countries, special care was taken to determine a suitable
sample size of patients for each country. As costs are
difficult to determine directly and are mostly triggered
by the hospitalization of the patients, the sample size
calculation was based on the rate of adverse events
(AEs) leading to, or prolonging, hospitalization.
Assuming a rate for the AEs that are leading to or
prolonging hospitalization and an absolute precision Δ,
the sample size N is calculated which is needed if the re-
spective 95% confidence interval (CI) should have a
length/precision of 2Δ (±Δ). Concretely, for DVT a
Table 1 Data documented at baseline and at 1, 3, 6 and 12 months follow-up
Variable Baseline Follow Up
Month 1 Month 3 Month 6 Month 12
Eligibility criteria (1) X
Baseline information (2) X
VTE risk factors and co- morbidities (3) X
Baseline information on VTE (4) X
VTE therapy (5) X X X X X
Current and previous treatment for prevention of stroke and other thromboembolic events (6) X X X X X
Quality of life (7) X X X X X
Patient satisfaction (8) X X X X X
PEmb-QoL Questionnaire (only PE-patients) X X X X X
Veines-QoL/Sym Questionnaire (only DVT-patients) X X X X X
Resource utilization (9) X X X X X
Clinical events and hospitalizations (10) X X X X X
Number of days in hospital, work days lost due to VTE, need for nursing/informal help X X X X X
Legend
(1) Objectively confirmed first-time or recurrent VTE; age ≥ 18 years, written informed consent
(2) (Socio-) demographic variables: age, gender, height, weight, BMI, blood pressure, graduation, education, employment status, insurance status
(3) Major surgery, bleeding history medical illnesses, multiple trauma, hip fracture, lower extremity paralysis, previous VTE, increasing age, cardiovascular or
respiratory failure, prolonged immobility, presence of central venous illness, estrogens, wide Varity of inherited and acquired hematological conditions, cancer,
chemotherapy etc
(4) Date of first diagnosis, lead symptoms, diagnostic pathways, severity
(5) Thrombolysis, Heparin, Vitamin K Antagonist, Embolectomy, Catheter, Insertion of V.cava filter
(6) Physician’s clinical impression of the risk of stroke/ thromboembolic events; physician’s use of algorithm to determine risk; current anticoagulation (by drug,
with information on continuation after the visit); discontinued anticoagulation (last 12 months); (Relative) contraindications to anticoagulation; INR (target and
achieved value, frequency of tests, percentage of values within target range) D
(7) EQ-5D
(8) PACT-Q2
(9) Number of physician contacts (own office, other physicians); VTE related productivity loss and costs; number and type of VTE diagnostic tests since last
visit /call
(10) Specifically due to: VTE, stroke, acute coronary syndrome including myocardial infarction, arterial embolism, decompensated heart failure, syncope,
bleeding events
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hospitalization rate of 12.3% was assumed [15], while for
PE a hospitalization rate of 17.9% was taken [16]. Fur-
thermore, for DVT as well as for PE, a relative precision
of 25% was assumed which corresponded to an absolute
precision of 0.031 for DVT and an absolute precision for
PE of 0.045. Based on these assumptions a minimum of
432 evaluable DVT patients were needed while for PE a
minimum of 279 evaluable patients were needed
(Table 2). Taking into account a dropout rate of 20% and
being aware of the fact that DVT and PE patients were
recruited in a ratio of 3:2 (DVT: PE), this resulted in a
total of 900 patients recruited (= 540 DVT patients +
360 PE patients) in each region and 4,500 patients in the
overall registry. The above sample size consideration is
taken from the observational plan and was made before
the start of the study. The primary parameters of interest
were the “costs” and the “rate for AEs leading to or
prolonging hospitalization” was taken as the main trigger
for this very general parameter. Therefore, the sample size
consideration should be taken as a general guidance and
needs to be interpreted in a flexible way. Based on real-life
experience, in general a sample of ~600 patients is consid-
ered as robust enough for reliable cost estimations.
Statistical analysis
This registry collected data under real life conditions.
The statistical analysis was performed in an explorative
and descriptive way. All variables collected in the elec-
tronic case report form as well as the data obtained from
the QoL assessments and all derived parameters were
used in the statistical analysis.
Binary, categorical, and ordinal parameters were sum-
marized by means of absolute and percentage numbers
within the various categories.
Numerical data was summarized by means of standard
statistics (i.e. number of available data, number of miss-
ing data, mean, standard deviation, minimum, median,
maximum, lower and upper quartile).
Time-to-event variables were analyzed via a Cox pro-
portional hazard regression model presenting hazard ra-
tios and the corresponding 95% CIs. No formal statistical
tests were performed within the statistical analysis.
A biometrical report using descriptive statistics of all
documented parameters was used to describe the overall
patient population as well as for each participating
country or by region. Patients violating any inclusion/ex-
clusion criteria were identified and documented. There
were several variables of interest for additional analyses
including: gender, age, weight, diabetes. Details on the
selection criteria used were given in the statistical ana-
lysis plan and in the statistical section of the report.
As the registry was exploratory in nature, and no
hypothesis testing was conducted, there were no signifi-
cance levels to be adjusted, and there was no require-
ment to provide stopping rules for the study.
The statistical analysis was performed using SAS
(release 9.2 or higher; Cary, NC, USA).
Discussion
Little is known about populations of unselected patients
with VTE. In Europe there is only minimal data describ-
ing individual patient characteristics, management pat-
terns, factors influencing health care resource utilization
and the corresponding costs. For completeness these
data need to be derived from confirmed cases within
hospitals, out of hospitals, in primary care or in special-
ized centers. The critical period for recurrences and
bleeding is the time between first diagnosis and the fol-
lowing 12 months. Including unselected patients with
both first time and recurrent VTE allows the burden of
disease to be quantified.
The PREFER in VTE registry will help to get a detailed
insight into the characteristics and management of pa-
tients with VTE (DVT and/or PE) with focus on preven-
tion of events (bleeding, recurrence of DVT, recurrence
of PE, post thrombotic syndrome, CV events, other
complications and death) in a real life setting. Data were
collected from VTE patients during the acute event and
followed by an observational period of up to 1 year and
were used to assess direct healthcare resource use and
estimated costs following acute first-time or recurrent
VTE. Patients were therefore treated on the discretion of
the physician in charge according to their regular med-
ical care.
In the past, most of the published information on the
current therapy and natural history of patients with VTE
comes from randomized clinical trials, with strict inclu-
sion and exclusion criteria, fixed doses of anticoagulant
drugs, and limited follow-up, mostly focused to obtain
data on efficacy and safety. However, a number of
Table 2 Sample size calculations
Assumed rate
of AE leading to,
or prolonging,
hospitalization
Assumed absolute precision
(relative precision)
Sample
size (without
drop-outs)
Sample
size (including
drop-outs)
DVT 0.123 0.031 (± 25%) 432 540
PE 0.179 0.045 (± 25%) 279 349
Sample size (for each region) for the assumed rate of AEs leading to, or prolonging hospitalization 0.123 (DVT) and 0.179 (PE) in order to achieve an absolute
precision of 0.031 (DVT) and 0.045 (PE) for a two-sided 95% CI. (Based on normal approximation, calculated by nQuery Advisor® 7.0.). AE, adverse event
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patients with VTE are never recruited in clinical tri-
als, particularly, the very young, the very elderly, the
pregnant, those with multiple comorbidities, those
with a high risk of bleeding and those with polyphar-
macy. Also there is scarce information on the current
therapy in real life (drugs, doses, duration and ap-
proach to patients with VTE recurrences and/or
bleeding complications). There is also limited infor-
mation regarding the QoL, utilization of resources,
costs, satisfaction of the patient and influence of their
willing on the duration of therapy. This information
may be very useful for patients, clinicians, healthcare
providers, health technology assessors and to the
pharmaceutical industry, who will all benefit from the
data about many aspects of VTE not previously con-
sidered in detail in a broad unselected population.
Currently, PREFER in VTE is the only registry evalu-
ating the management of acute VTE in Europe; on an
international level, the management of acute VTE has
been assessed in the RIETE registry and in the on-
going GARFIELD-VTE registry [20,21].
The observational PREFER in VTE registry aims to
address these questions by describing the current anti-
coagulant treatment patterns, pathways of clinical care,
clinical outcomes as well as patient’s treatment satisfac-
tion and HR-QoL in a real world setting. Real life data
are of utmost importance to collect information on the
safety, efficacy and drug utilization of any novel drug
and to link the data with the regulatory mandated phase
III data. This is an important stage in the observation
and stringent control of all novel drugs. Therefore, there
is a need for a European Union wide, international ob-
servational registry of VTE patients treated in everyday
clinical practice to provide complementary data to that
from the trials and to fully understand the treatment
pathway of patients.
This large, European registry of acute VTE patients
allows the opportunity to answer several research ques-
tions that have not previously been investigated within a
non- randomized, non-selected population. These ques-
tions will address the following six areas:
1. Patient characteristics of consecutive patients with
acute VTE in clinical practice including
comorbidities, history of thromboembolic/bleeding
events, temporary and permanent risk factors
including severe medical disorders and interventions
with VTE risk
2. Diagnosis of acute VTE (first-time [initial] or
recurrent) including timing, symptoms and signs,
clinical status and severity
3. Patient pathways including referral details and
related time intervals (from primary to secondary
care, e.g., internist, hematologist, vascular surgeon
or physician, cardiologist and/or hospital) as well as
diagnostic pathways
4. Drug utilization/use pattern of drugs for treatment
of VTE and prevention of related events
5. Health related quality of life including patient
satisfaction and real-world assessments of quality
of life
6. Resource consumption/Health care utilization.
Conclusions
The PREFER in VTE registry will provide valuable in-
sights into all these factors in patients with VTE and
their acute and mid-term management. The study will
provide the opportunity to identify differences in man-
agement and outcomes across care settings, and will
offer clarity relating to the effectiveness of anticoagula-
tion treatment strategies to treat acute VTE and to pre-
vent recurrent VTE events.
Appendix
List of PREFER in VTE investigators.
Austria
Marianne Brodmann, Peter Rief, Universitätsklinikum
Graz, Graz; Lisbeth Eischer, Slagjana Stoshikj,
Medizinische Universität Wien, Wien; Michael Hirschl,
Serge Weinmann, Landesklinikum Zwettl, Zwettl; Peter
Marschang, Universitätsklinik Innsbruck für Innere
Medizin, Innsbruck.
France
Fabrice Abbadie, Centre hispitalier Jacques Lacarin,
Vichy; Antoine Achkar, CHI Eure et Seine – Site de
Vernon, Vernon; Azeddine Addala, Perrone Reynaldo,
Lyon; Frédéric Adnet, Hopital Avicenne, Bobigny; Jean-
François Alexandra, Hopital Bichat Claude Bernard,
Paris; Sandro Aquilanti, Espace ARTOIS Santé, Arras;
Abdelkader Belhassane, Centre Hospitalier de Cambrai,
Cambrai Cedex; Anne Benaroya, Pole Sante Des Aspres,
Thuir; Toufek Berremili, Marie Chevallier Grenot, CH
Annecy Genevois, Pringy Cedex; Virginie Birr, Daniela
Holtea, CHU Emile Muller, Mulhouse Cedex; Christophe
Bonnin, Le Gibraltar 10–12, Nice; Frederic Bosler, 19 rue
Robert Schumann, Sarrebourg; Marie-Gabrielle Bresin
Durand, Résid des remparts 7 rue des lombards,
Hennebont; Dominique Brisot, Centre Commercial La
Croisee, Clapier; Christophe Brousse, Tarodo De La
Fuente, Clinique Du Parc, Castelnau-le-Lez; Richard
Cayman, 8 rue des des de l'aire, Bourgoin Jallieu;
Michèle Cazaubon, 17, rue Mesnil, Paris; Olivier
Champion, 6 Avenue Georges Pompidou, Chalon-sur-
Saône; Myriam Chanut, Immeuble Le Clos de
Bellande, Aubenas; Pascal Chevalet, Hopital Bellier,
Nantes; Jerome Connault, Cecile Durant, CHU Hôtel-
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Dieu de Nantes, Nantes; Joel Constans, Hopital St Andre,
Bordeaux; Mihaela Cordeanu, CHRU Strasbourg,
Strasbourg; Francis Couturaud, Karine Lacut, CHRU
Hopital Cavale Blanche, Brest; Laure De Dedker, François
Xavier Piloquet, Hôpital Nord Laennec, Saint Herblain;
Eric Decoulx, Centre Hospitalier de Tourcoing, Tour-
coing; Benoit Derrien, Centre Hospitalier, Le Mans
Cedex 9; Jean-Marc Diamand, Centre De Medecine
Vasculaire, Grenoble; Antoine Diard, 25 Route De
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